Exact Sciences is facing backlash for sending unsolicited Cologuard colon cancer screening kits to consumers, sparking ...

During his time at RCH, Dr Sriniworn observed a wide range of advanced paediatric surgical procedures, with a focus on ...

BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...

"In Italy, every 25 minutes we have a death from colorectal cancer, one of the 'big killers' in oncology if not diagnosed in ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an ...

Risk for venous thromboembolism (VTE) after an operation for colorectal cancer (CRC) is higher among patients with inflammatory bowel disease (IBD), according to results of a population-based cohort ...

A recurrence risk of less than 0.5% at 6 years after surgery may provide a practical definition of “cure” in the setting of colon cancer.